Abstract
Anti-clinically amyopathic dermatomyositis (CADM)-140/MDA5 autoantibodies are specifically detected in patients with dermatomyositis and are known to have a strong association with rapidly progressive interstitial lung disease (RP-ILD). Here we report an amyopathic dermatomyositis (ADM) patient who developed RP-ILD characterized by elevated anti-CADM-140/MDA5 titer. Respiratory symptoms gradually improved, and anti-CADM-140/MDA5 titer decreased in parallel to below the cutoff level. It may be useful to quantify CADM-140-specific autoantibodies for monitoring disease activity in patients with ADM and RP-ILD.
MeSH terms
-
Autoantibodies / blood*
-
Autoantibodies / immunology
-
Cyclosporine / therapeutic use
-
Dermatologic Agents / therapeutic use
-
Dermatomyositis / complications
-
Dermatomyositis / immunology
-
Dermatomyositis / pathology*
-
Drug Therapy, Combination
-
Female
-
Glucocorticoids / therapeutic use
-
Humans
-
Intercellular Signaling Peptides and Proteins
-
Lung Diseases, Interstitial / complications
-
Lung Diseases, Interstitial / immunology
-
Lung Diseases, Interstitial / pathology*
-
Middle Aged
-
Peptides / blood*
-
Peptides / immunology
-
Prednisolone / therapeutic use
-
Treatment Outcome
Substances
-
Autoantibodies
-
CADM-140 peptide, human
-
Dermatologic Agents
-
Glucocorticoids
-
Intercellular Signaling Peptides and Proteins
-
Peptides
-
Cyclosporine
-
Prednisolone
Supplementary concepts
-
Amyopathic dermatomyositis